Background: Cutaneous melanoma is an increasingly common and potentially lethal form of skin cancer. Current staging systems based on clinical and pathological features have limitations in accurately predicting outcomes, particularly for early-stage disease. The 31-gene expression profile (31-GEP) test has emerged as a promising tool for improving risk stratification in melanoma patients. Methods: We conducted a systematic review and meta-analysis of studies evaluating the prognostic performance of the 31-GEP test in cutaneous melanoma. A comprehensive literature search was performed in multiple databases. Studies reporting survival outcomes stratified by 31-GEP class were included. Random-effects models were used to determine survival estimates across studies. Results: Thirteen studies comprising 14,760 patients were included in the meta-analysis. The 31-GEP test consistently stratified patients into risk groups with significantly different outcomes. The 5-year melanoma-specific survival rates were 99.8% (95% CI: 98–100%) for Class 1A, 97.6% (95% CI: 92.4–99.3%) for Class 1B/2A, and 83.4% (95% CI: 66.5–92.7%) for Class 2B. Similar trends were observed for recurrence-free and distant metastasis-free survival. Conclusions: This meta-analysis supports the prognostic utility of the 31-GEP test in cutaneous melanoma prognostication. The test consistently stratified patients into clinically meaningful risk groups across multiple survival metrics. These findings support the potential clinical utility of the 31-GEP test in enhancing current staging systems and informing personalized management strategies for melanoma patients.
背景：皮肤黑色素瘤是一种日益常见且具有潜在致命性的皮肤癌。目前基于临床和病理特征的TNM分期系统在准确预测预后方面存在局限性，尤其对于早期疾病。31基因表达谱（31-GEP）检测已成为改善黑色素瘤患者风险分层的有前景工具。 方法：我们对评估31-GEP检测在皮肤黑色素瘤中预后性能的研究进行了系统综述和荟萃分析。通过多个数据库进行全面的文献检索，纳入按31-GEP分类报告生存结局的研究，并采用随机效应模型确定跨研究的生存估计值。 结果：荟萃分析共纳入13项研究，涵盖14,760例患者。31-GEP检测能持续将患者分层为具有显著不同结局的风险组：1A类患者的5年黑色素瘤特异性生存率为99.8%（95% CI：98–100%），1B/2A类为97.6%（95% CI：92.4–99.3%），2B类为83.4%（95% CI：66.5–92.7%）。无复发生存和无远处转移生存也呈现相似趋势。 结论：本荟萃分析证实31-GEP检测在皮肤黑色素瘤预后评估中的有效性。该检测能基于多项生存指标，持续将患者分层为具有临床意义的风险组。这些发现支持31-GEP检测在增强现有分期系统、指导黑色素瘤患者个体化管理策略方面的潜在临床价值。
肿瘤(癌症)患者之家